Cardiac surgery Instruments Market Analysis

Global Cardiac Surgery Instruments Market Overview

Cardiac Surgery Instruments Market Size was valued at USD 1.7 billion in 2022 and is projected to grow from USD 1.8377 Billion in 2023 to USD 3.38 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.1% during the forecast period (2023 - 2032).

In the upcoming years, growth can be attributable to several variables, including rising diabetes incidence, cardiovascular disease prevalence, and healthcare costs are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

In August 2023, GE HealthCare introduced the Vscan Air SL, a handheld ultrasound device, at the European Society of Cardiology (ESC) Congress in Amsterdam, the Netherlands. This device combines proprietary image enhancing technology and the capability to perform both vascular and cardiac assessments at the point of care. 

GE HealthCare stated that the Vscan Air SL, a handheld ultrasound instrument, provides improved sensitivity and resolution by utilizing the patented SignalMax and XDclear technology. According to GE HealthCare, the Vscan Air SL has a dual-headed probe that allows physicians to access sector and linear arrays on the same device. This capacity makes it easier for clinicians to quickly analyze the vascular and heart health of patients. GE HealthCare announced that the Vscan Air SL, which has received FDA 510(k) clearance, will be released for sale in the United States in the coming month. According to the business, the device is currently available in Austria, New Zealand, and many nations in Asia and Europe.

In June 2023, Magenta Medical, a device manufacturer located in Israel, is starting an early feasibility study with their Elevate percutaneous Left Ventricular Assist Device (pLVAD) for high-risk percutaneous coronary intervention (HR-PCI). This research is the initial phase in the process of obtaining FDA clearance. As the tiniest cardiac pump in the world, it offers temporary mechanical assistance to the circulatory system during HR-PCI treatments. Individuals diagnosed with coronary artery disease frequently require a catheterisation operation to alleviate the blockage in the arteries that provide blood to the heart. 

During coronary intervention, there may be instability in more severe and high-risk situations. In such instances, the utilization of mechanical circulatory support becomes advantageous as it serves to uphold systemic blood pressure and sustain the perfusion of crucial organs, including the heart. Restricting the insertion profile of the device is crucial in order to reduce difficulties related to vascular access. Conventional LVAD devices are somewhat bulky and necessitate a surgical procedure involving the opening of the heart for installation. Nevertheless, the Elevate device can be placed through a minor hole in the groin and then enlarged upon reaching the left ventricle of the heart. The pump's flow can be customized to meet the patient's requirements, with a maximum mean flow rate of 5 L/min.

According to a Medtronic Plc announcement, the Affera, Inc. acquisition was completed in August 2022 and it is a world leader in healthcare technology. The first-ever cardiac mapping and navigation platform combined with radiofrequency ablation solution using a targeted pulsed field and distinct diagnostic technology are just some of the company’s offerings for cardiac ablation.

The Guardian device, Angel Medical Systems’ major product, had its first commercial implantation in the United States in July 2021. This marked their initial surgery following the most recent FDA approval they got.

Boston Scientific exercised its option to buy Farapulse, Inc., which added up to include currently available only commercially accessible cardiac pulsed-field ablation technology into its electrophysiology suite as of June 2021.

Phoenix Cardiac Devices announced in April 2021 that their BACE (Basal Annuloplasty of the Cardio Externally) device has been CE Marked. This is what facilitates marketing BACE within the European Union.

Medtronic Private Limited will be launching Azure pacemaker BlueSync technology in India this October 2020. With this technological novelty, patients’ smartphones and tablets can directly communicate with BlueSync-enabled devices.

In June 2020, Boston Scientific announced the launch of DIRECTSENSE technology in America. It is normally used during cardiac ablations to monitor how radiofrequency energy is working.

In February 2020, Medtronic PLC received US FDA approval for Leadless Micra AV –the smallest pacemaker worldwide with atrioventricular (AV) synchrony.

Symmetry Surgical, Inc., a leading surgical instrumentation and solutions company in January 2020, completed an acquisition of The O.R. Company, which manufactures innovative surgical devices for minimally invasive and open surgeries.

With cardiac surgery equipment, structural flaws in the circulatory system can be fixed during open-heart surgery. These procedures include coronary artery bypass grafting, abdominal aortic aneurysm repair, congenital heart problems, ventricular remodeling, and installing cardiac assist devices. This advancement fuels the demand for specialized equipment for minimally invasive heart surgery. Technology advancements, such as the introducing of robotic-assisted surgeries, contribute to the market's revenue growth. Cardiothoracic surgery involves equipment like heart-lung machines, which are most frequently utilized to execute a cardiopulmonary bypass. Additionally, there is a global scarcity of practicing cardiac surgeons. Gadgets for cardiac surgery are being produced in response to patient needs due to industry technological breakthroughs.

As a result, leading companies in the market for cardiac surgical equipment are introducing cutting-edge technologies and designs to boost their market share. Additionally, there is a higher need for cardiac surgical equipment due to the rise in cardiovascular illness, particularly in the elderly. These illnesses, which account for one-third of all fatalities worldwide, will probably continue contributing to mortality and morbidity. The demand for cardiologists is expected to double during the projected period, based on growth and aging, if existing healthcare consumption and service pattern persists. This is due to increased cardiac procedures and the senior population, who have a greater tendency. Consequently, this rising demand is anticipated to generate substantial opportunities for physicians and manufacturers in the cardiac surgery instruments market.

Globally, one of the leading causes of death is cardiovascular disease. This advancement is fueling an increase in demand for heart surgical equipment globally. Also contributing to the market's revenue growth is the aging population, which is more prone to cardiovascular diseases and requires more medical interventions. However, the primary market forces boosting the rate of expansion of the cardiac surgical tools market revenue are the rise in the prevalence of various cardiovascular diseases globally, the quickening pace of technological advancement, and the rising need for less invasive procedures.

Cardiac Surgery Instruments Market Trends

• Growing Prevalence of Cardiac Conditions Worldwide to boost the market growth

The main causes of heart disease in people worldwide are junk food consumption, sedentary lifestyles, and mental stress. According to WHO, 17.9 million people globally die from cardiovascular illnesses, accounting for around 31.0% of all fatalities. Around 23.6 million deaths from cardiovascular diseases are anticipated by 2030. Moreover, smoking and using tobacco products may be to blame for a sizable portion of these fatalities. More than 8 lakh Americans died in 2016 due to cardiovascular disorders, according to research conducted by the American Heart Association. It has been noted that these illnesses cause more fatalities than both cancer and chronic lower respiratory disease put together. Cardiovascular disorders cause over 2,300 daily deaths in Americans, or one every 38 seconds.  Thus driving the market CAGR.

For Instance, according to Medtronic's annual report for the fiscal year 2022, the technology business saw an increase in revenue due to the worldwide procedure volumes rebounding from the reduction caused by the COVID-19 pandemic in the first and second quarters of the fiscal year 2021.

However, Rapid technical development, growth in the prevalence of different cardiovascular illnesses worldwide, and growing demand for less invasive procedures are the main market drivers driving the growth of the cardiac surgery instruments market revenue.

Cardiac Surgery Instruments Market Segment Insights

Cardiac Surgery Instruments Product Insights

Based on product, the Cardiac Surgery Instruments Market segmentation includes Forceps, Clamps, and Scalpels. The forceps segment has the most share and is anticipated to increase the fastest. Increased cardiac procedures and the accessibility of various tools, including gripping and vascular forceps. The frequent use of forceps in many cardiac procedures also contributes to this rise. For Instance, AccurKardia and Mawi, a producer of medical-grade wearables in the cardiac market, will work together in October 2022 to include AccurKardia's unique ECG analytics into Mawi's new cardiac monitoring watch. This partnership demonstrates AccurKardia's dedication to providing solutions for remote patient monitoring that will enable top-notch cardiac care.

However, the scalpel market is predicted to expand quickly and is the second fastest-growing after forceps. Due to its application in various cardiac procedures, including heart transplants, coronary arteries, heart valves, and pediatric surgeries, this market is anticipated to develop at a CAGR of 6.9% over the projected period. These scalpels come in various sizes and forms for different sorts of operations.

 January 2020: The O. R. Company was bought by Symmetry Inc. It creates, produces, and develops cutting-edge surgical and medical equipment and technologies, ranging from specialized consumables to exclusive, minimally invasive and open procedures.

Cardiac Surgery Instruments Application Insights

The Cardiac Surgery Instruments Market segmentation based on application includes Coronary Artery Bypass Grafting, Heart Valve Surgery and Pediatric Surgery. The biggest market, CABG, is predicted to continue to expand profitably during the foreseeable timeframe. In 2022, the Coronary Artery Bypass Grafting (CABG) category held the biggest market share, and it is projected to continue to develop quickly over the coming years. Coronary artery disease, which comes from a buildup of fatty material inside the arteries, narrows the coronary arteries. It is predicted that growth would be facilitated by the disease's predicted rise in prevalence because surgery is needed to treat this ailment. Due to the rise in heart valve procedures, Heart Valve Surgery holds the market's second-largest sector, and it is projected to expand at a CAGR of 6.81% over the coming years. Devices for heart valve surgery are used to treat blood clots, heart attacks, and heart failure. The main treatment for a damaged heart valve is open surgery, which involves implanting a new valve. These factors will likely drive the demand for cardiac surgery instruments market growth.

Cardiac Surgery Instruments End User Insights

The end-user has bifurcated the Cardiac Surgery Instruments Market data into Hospitals & Clinics and Ambulatory Surgical Centers. Throughout the projection period, the hospitals & clinics segment is predicted to have the most share. A developed infrastructure, heavy traffic, and healthcare spending increase explain this. Moreover, the hospitals & clinics category is anticipated to develop faster than average during the projected period due to increased operations brought on by the rising frequency of cardiac illnesses and other conditions. Growth is also being fueled by the rise of medical facilities worldwide due to government efforts. Moreover, development is aided by an increase in operating rooms brought on by the strong demand for heart surgery has further broadened the growth opportunity for the cardiac surgery instruments industry.

Figure 1: Cardiac Surgery Instruments Market, by End User, 2022 & 2030 (USD Million)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

According to representatives from the business, the straightforward import of medical and surgical equipment has been embroiled in regulatory red tape in addition to the nation's financial crisis. Healthcare Devices Association of Pakistan (HDAP) reported that the Drug Regulatory Authority of Pakistan (DRAP)'s (erroneous policies) had hampered the flow of medical supplies throughout the nation, increasing concerns about delays in life-saving operations. The group has highlighted concerns about a crisis in the availability of medical facilities due to the challenges encountered in importing machinery and medical equipment into the nation. It stated that DRAP has mandated medical device registration. Import policy was then changed to require a DRAP certificate. Most registration applications received over the years have not been resolved by DRAP, which has impeded the equipment's easy import.

Cardiac Surgery Instruments Regional Insights

By Region, the study provides the Cardiac Surgery Instruments market insights into North America, Europe, Asia-Pacific and Rest of the World. Due to its developed healthcare industry, North America Cardiac Surgery Instruments market led the highest share in 2022. The region is also anticipated to be driven by an increase in operations and a rise in heart problems. Also, the widespread use of cutting-edge surgical instruments and equipment fosters development.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: GLOBAL CRYOTHERAPY AND CRYOSURGERGY MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe cardiac surgery instruments market accounts for the second-largest market share due to the expanding senior population. It will help Europe gain a sizable market share throughout the forecast period. The healthcare industry is developing, and the use of cutting-edge medical items is increasing. Further, the Germany cardiac surgery instruments market held the largest market share, and the UK cardiac surgery instruments market was the fastest-growing market in the European region

The Asia-Pacific Cardiac Surgery Instruments Market is expected to grow at the fastest CAGR from 2022 to 2030. Important influences include developing the healthcare system and reimbursement procedures in developing countries. Also, a rise in cardiac operations is anticipated to support growth during the forecast period. Moreover, China cardiac surgery instruments market held the largest market share, and the India cardiac surgery instruments market was the fastest-growing market in the Asia-Pacific region

Cardiac Surgery Instruments Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the cardiac surgery instruments market grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the cardiac surgery instruments industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies manufacturers adopt in the global cardiac surgery instruments industry to benefit clients and expand the market sector is manufacturing locally to reduce operating costs. In recent years, the cardiac surgery instruments industry has provided medicine with some of the most significant benefits. In the cardiac surgery instruments market, major players such as B. Braun Melsungen AG KIS Martin Group, Teleflex Incorporated, Sklar Surgical Instruments, and Symmetry Surgical Inc. are working on expanding the market demand by investing in research and development activities.

A group of medical experts from Germany called Medicon eG includes doctors, dentists, and other healthcare practitioners. Promoting top-notch healthcare services and assisting its members in their day-to-day work are the primary objectives of Medicon eG. The cooperative offers a variety of services to its members, including access to cutting-edge medical equipment, training and education programs, and administrative and financial assistance. For Instance, in 2021, Medicon eG announced the release of its new minimally invasive cardiac surgery instruments, designed to reduce the invasiveness of cardiac surgery procedures and improve patient outcomes.

Also, Symmetry Surgical provides its customers with various surgical instrument sets and accessories, including instruments for general surgery, gynecology, orthopedics, neurosurgery, and more. For Instance, in 2021, Symmetry Surgical also introduced a new line of minimally invasive instruments designed to reduce the invasiveness of cardiac surgery procedures and improve patient outcomes.

Key Companies in the cardiac surgery instruments market includes

• Braun Melsungen AG KIS Martin Group


• Teleflex Incorporated


• Sklar Surgical Instruments


• Symmetry Surgical Inc


• Medicon eG


• STILLE


• Delacroix-Chevalier


• Cardivon Surgical Inc.


• Wexler Surgical


• Boss Instruments Ltd


• Scanlan International, among others

Cardiac Surgery Instruments Industry Developments

October 2022: The United States FDA has given Medtronic plc permission for extended labeling of a cardiac lead that uses the heart's natural electrical circuitry to deliver essential treatment while avoiding problems like cardiomyopathy frequently associated with conventional pacing techniques.

October 2022:  The HELIOSTAR Balloon Ablation Catheter was introduced in Europe by Biosense Webster, Inc., a Johnson & Johnson MedTech subsidiary. When used with a suitable multi-channel RF generator, the HELIOSTAR Balloon Ablation Catheter is approved for cardiac ablation and catheter-based cardiac electrophysiological mapping (stimulating and recording) of the atria.

Cardiac Surgery Instruments Market Segmentation

Cardiac Surgery Instruments Type Outlook

• Forceps


• Clamps


• Scalpels

Cardiac Surgery Instruments Device Type Outlook

• Coronary Artery Bypass Grafting


• Heart Valve Surgery


• Pediatric Surgery

Cardiac Surgery Instruments Application Outlook

• Hospitals & Clinics


• Ambulatory Surgical Centers

Cardiac Surgery Instruments Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America